CEO: Maarten de Chateau
Description: Sixera Pharma is a biopharmaceutical company with expertise in dermatology, and especially rare genetic skin diseases (genodermatoses). We are focusing our drug development effort on protease biology in the skin and have developed a series of compounds targeting certain skin proteases (kallikreins) known to cause a rare inherited skin disease called Netherton’s syndrome. The lead compound is currently undergoing IND enabling studies.
CEO: Johan Sandin
CEO Janssen, Nordic: Lars Johansson
Web: www.janssen.com/sweden and www.janssen.com
About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
CEO: Jonas Ekblom
About Promore Pharma AB
Promore Pharma is a small biopharmaceutical company specialized in the development of therapeutic peptides for local application in wounds and skin infections. The company’s vision is to develop a portfolio of unique first-in-class products in the field of advanced wound care. The current development pipeline includes several therapeutic peptides in clinical development, with potential for use in several medical applications. Please visit our web site: www.promorepharma.com.
CEO: Per Lundin
Scientific Director of European Initiatives, SGC: Michael Sundström
Web: www.thesgc.org and www.ultra-dd.org
Description: SGC (founded in 2003) catalyses research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of human biology and diseases. SGC accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in eight global pharmaceutical companies. Michael Sundström, leading the Stockholm based operations, holds the position as Scientific Director for European Initiatives for SGC and is part of the SGC Global Management Team. He is also the Scientific Director for ULTRA-DD, the IMI funded project within this confederation of projects, having around 300 scientists at six different Universities in Brazil, Canada, US, UK, Sweden and Switzerland. www.thesgc.org and www.ultra-dd.org
CEO: Anders Kronström
Description: Biosergen AS is a biotech company developing new drugs based on cutting edge biosynthetic engineering of natural products, combined with chemical synthesis. Established in 2004, the company is based in Trondheim, Norway and focuses its innovative research on fighting systemic fungal infections. Biosergen’s lead compound, BSG005, is currently in pre-clinical development phase.
The company is currently focusing on delivering a proof-of-concept program for BSG005 as well as on seeking partners for out-licensing and the continued development of BSG005.
The current major owners of Biosergen are Karolinska Development AB, Rosetta Capital, Östersjöstiftelsen, and Sintef Venture II.